Lakefront Biotherapeutics NV (LKFT) — Strategic Asset Allocation Index
Lakefront Biotherapeutics NV (LKFT) has a Strategic Asset Allocation Index of 2.3% as of June 2026. Strategic assets (PP&E of $- plus long-term investments of $73.86 Million) total $73.86 Million, measured against net assets of $3.26 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check LKFT tangible net worth ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Lakefront Biotherapeutics NV Strategic Asset Allocation Index (2022–2025)
This chart shows how Lakefront Biotherapeutics NV's Strategic Asset Allocation Index has evolved across 4 annual periods from 2022 to 2025. As of June 2026, the index stands at 2.3%, representing strategic assets of $73.86 Million against net assets of $3.26 Billion USD.
Annual Strategic Asset Allocation Index for Lakefront Biotherapeutics NV (2022–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Lakefront Biotherapeutics NV from 2022 to 2025, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Lakefront Biotherapeutics NV (LKFT) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1.4% | $46.81 Million | $- | $46.81 Million | $3.24 Billion | ▼ -7.3 pp |
| 2024 | 8.7% | $253.12 Million | $- | $253.12 Million | $2.90 Billion | ▲ +8.3 pp |
| 2023 | 0.5% | $13.57 Million | $- | $13.57 Million | $2.80 Billion | ▲ +0.5 pp |
| 2022 | 0.0% | $0.00 | $- | $0.00 | $2.53 Billion | — |